BioCentury | Feb 5, 2020
Product Development

2019-nCoV drug discovery: HHS funds Regeneron mAbs and BenevolentAI deploys machine learning

Regeneron and BenevolentAI unveiled a deal and a platform, respectively, on Tuesday that could yield therapies against 2019-nCoV that go beyond anti-inflammatory drugs for other viral infections. The first nine clinical trials of medicines for...
BioCentury | Jan 31, 2020
Distillery Therapeutics

TNFR2 and IL-33 identified as targets in Dupuytren's disease

DISEASE CATEGORY: Musculoskeletal INDICATION: Dupuytren's disease Inhibiting TNFR2 and IL-33 could treat Dupuytren's disease, which is characterized by progressive fibrosis of the palmar and digital fascia. The effector cells in Dupuytren's, the myofibroblasts, mediate the...
BC Extra | Jan 31, 2020
Clinical News

A dozen vaccine programs under way as WHO declares coronavirus public health emergency

WHO declared the coronavirus outbreak a Public Health Emergency of International Concern Thursday and called for China and countries around the world to take public health steps to contain the virus. WHO also stressed the...
BioCentury | Jan 29, 2020
Product Development

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

Under the leadership of incoming CEO Laurence Reid, hearing loss company Decibel is starting its next chapter in drug discovery with a narrowed focus on inner ear cell regeneration and programs in balance disorders. Reid...
BC Extra | Jan 29, 2020
Company News

Jan. 28 Company Quick Takes: Kite, Alkermes, Regeneron-Sanofi, Incyte, NantHealth-NantOmics, Sorrento, MicroCures, Paion-Mundipharma

Kite’s KTE-X19 under review in Europe   EMA has accepted an MAA for KTE-X19 from Kite, positioning the CAR T cell therapy from the Gilead Sciences Inc. (NASDAQ:GILD) unit to become the first CAR T...
BC Extra | Jan 28, 2020
Company News

DARPA-funded AbCellera to pursue mAbs to treat coronavirus outbreak

AbCellera Biologics Inc. has started a program to discover mAbs as potential treatments for patients infected with the 2019-nCoV that was first identified in Wuhan, China, the company’s CEO, Carl Hansen, told BioCentury. The work...
BioCentury | Jan 25, 2020
Product Development

The race is on to develop therapies and vaccines for the coronavirus outbreak

Public release of the genetic sequence of the coronavirus first detected in Wuhan, China acted as a starter pistol, setting off a race to develop medical countermeasures. Beyond the potential for containing and hopefully eradicating...
BC Extra | Jan 24, 2020
Clinical News

Ipsen’s $1B bet on Clementia fizzles with FOP trial stop

Ipsen has paused the clinical program for palovarotene in FOP, the asset behind its $1 billion acquisition of Clementia. The move puts the CVR that came with the deal at serious risk and could give...
BC Extra | Jan 23, 2020
Clinical News

Biopharma companies, academics, governments racing to develop medical countermeasures against novel coronavirus

The rapid sharing of the genetic sequence of the 2019 novel coronavirus (2019-nCoV), first identified in Wuhan, China, has sparked an extraordinary response from biopharma companies, academic researchers and governments. At least seven initiatives to...
BC Extra | Jan 17, 2020
Preclinical News

Jan 16 Preclinical Quick Takes: Deerfield's Orchard partners with Yeda; Acuitas-Penn flu vaccine in newborns; plus Regeneron, Genentech-Gladstone and Banyan

Deerfield forms Orchard Innovations in Yeda collaboration on translation  Deerfield Management Co. launched Orchard Innovations LLC to pursue translational R&D derived from Weizmann Institute of Science research. Yeda Research and Development Co. Ltd., Weizmann’s commercial...
Items per page:
1 - 10 of 1658
BioCentury | Feb 5, 2020
Product Development

2019-nCoV drug discovery: HHS funds Regeneron mAbs and BenevolentAI deploys machine learning

Regeneron and BenevolentAI unveiled a deal and a platform, respectively, on Tuesday that could yield therapies against 2019-nCoV that go beyond anti-inflammatory drugs for other viral infections. The first nine clinical trials of medicines for...
BioCentury | Jan 31, 2020
Distillery Therapeutics

TNFR2 and IL-33 identified as targets in Dupuytren's disease

DISEASE CATEGORY: Musculoskeletal INDICATION: Dupuytren's disease Inhibiting TNFR2 and IL-33 could treat Dupuytren's disease, which is characterized by progressive fibrosis of the palmar and digital fascia. The effector cells in Dupuytren's, the myofibroblasts, mediate the...
BC Extra | Jan 31, 2020
Clinical News

A dozen vaccine programs under way as WHO declares coronavirus public health emergency

WHO declared the coronavirus outbreak a Public Health Emergency of International Concern Thursday and called for China and countries around the world to take public health steps to contain the virus. WHO also stressed the...
BioCentury | Jan 29, 2020
Product Development

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

Under the leadership of incoming CEO Laurence Reid, hearing loss company Decibel is starting its next chapter in drug discovery with a narrowed focus on inner ear cell regeneration and programs in balance disorders. Reid...
BC Extra | Jan 29, 2020
Company News

Jan. 28 Company Quick Takes: Kite, Alkermes, Regeneron-Sanofi, Incyte, NantHealth-NantOmics, Sorrento, MicroCures, Paion-Mundipharma

Kite’s KTE-X19 under review in Europe   EMA has accepted an MAA for KTE-X19 from Kite, positioning the CAR T cell therapy from the Gilead Sciences Inc. (NASDAQ:GILD) unit to become the first CAR T...
BC Extra | Jan 28, 2020
Company News

DARPA-funded AbCellera to pursue mAbs to treat coronavirus outbreak

AbCellera Biologics Inc. has started a program to discover mAbs as potential treatments for patients infected with the 2019-nCoV that was first identified in Wuhan, China, the company’s CEO, Carl Hansen, told BioCentury. The work...
BioCentury | Jan 25, 2020
Product Development

The race is on to develop therapies and vaccines for the coronavirus outbreak

Public release of the genetic sequence of the coronavirus first detected in Wuhan, China acted as a starter pistol, setting off a race to develop medical countermeasures. Beyond the potential for containing and hopefully eradicating...
BC Extra | Jan 24, 2020
Clinical News

Ipsen’s $1B bet on Clementia fizzles with FOP trial stop

Ipsen has paused the clinical program for palovarotene in FOP, the asset behind its $1 billion acquisition of Clementia. The move puts the CVR that came with the deal at serious risk and could give...
BC Extra | Jan 23, 2020
Clinical News

Biopharma companies, academics, governments racing to develop medical countermeasures against novel coronavirus

The rapid sharing of the genetic sequence of the 2019 novel coronavirus (2019-nCoV), first identified in Wuhan, China, has sparked an extraordinary response from biopharma companies, academic researchers and governments. At least seven initiatives to...
BC Extra | Jan 17, 2020
Preclinical News

Jan 16 Preclinical Quick Takes: Deerfield's Orchard partners with Yeda; Acuitas-Penn flu vaccine in newborns; plus Regeneron, Genentech-Gladstone and Banyan

Deerfield forms Orchard Innovations in Yeda collaboration on translation  Deerfield Management Co. launched Orchard Innovations LLC to pursue translational R&D derived from Weizmann Institute of Science research. Yeda Research and Development Co. Ltd., Weizmann’s commercial...
Items per page:
1 - 10 of 1658